Jan. 28, 2025 — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo Embolic System. The Tembo Embolic System is a bioresorbable1 embolization agent comprised of irregularly shaped, dry gelatin particles of a size range from 85-255µm1. These particles are designed for the embolization of hypervascular tumors and blood vessels to occlude blood flow in the peripheral vasculature.

Jan. 28. 2025 — Researchers have developed a new software tool that provides unprecedented capabilities to see inside 3D images. Its interactive, dynamic cutaway views allowed them to analyze never-before-seen dynamics of embryonic mouse heart development using optical coherence tomography (OCT) images.

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE HealthCare have launched a Care Innovation Hub, a joint research collaboration to address meaningful clinical challenges in three key areas: accessibility to advanced medical imaging; non-invasive diagnosis and management of neurological; and neurodegenerative disease, and precision oncology.

GRACE Breast Imaging & Medical Spa of Iowa, with locations in Urbandale and Clive, recently became the first healthcare facility in the United States to install the Siemens Healthineers'  Mammomat B.brilliant — a newly redesigned mammography platform. The Mammomat B.brilliant includes new 3D image acquisition and image reconstruction technology as well as features for full-field digital mammography, or two-dimensional breast imaging; breast biopsy; and titanium contrast-enhanced mammography.

Jan. 23, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a new study in the Journal of Clinical Oncology Precision Oncology. Conducted in collaboration with Japan’s National Cancer Center Hospital East (NCCHE), the study reveals how Lunit’s AI-powered pathology solutions, Lunit SCOPE HER2 and Lunit SCOPE IO, significantly improve HER2 biomarker evaluation and the prediction of clinical outcomes in metastatic colorectal cancer (mCRC) patients undergoing HER2-targeted therapy.

Jan. 22, 2025 — Public Responsibility in Medicine and Research (PRIM&R) recently called for establishing clear ethical guidelines to ensure data research is conducted responsibly. PRIM&R’s statement is part of the national nonprofit’s comment submission to the National Telecommunications and Information Administration (NTIA), regarding the potential development of ethical guidelines for research using “pervasive data.”

Jan. 21, 2025 — The NeurEYE research team, led by the University of Edinburgh, with Glasgow Caledonian University, has collected almost 1 million eye scans from opticians across Scotland, forming the world’s largest data set of its kind.

Jan. 8, 2025 – The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer’s Association have released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimer’s disease and other dementias. The new criteria expand PET imaging guidance to include tau PET, incorporate updated information, and provide specific guidance to enhance diagnostic precision, treatment decisions, and patient care.

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).

All QUANTI studies investigated gadoquatrane at a gadolinium dose of 0.04 mmol Gd/kg body weight which represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. Gadoquatrane successfully met the primary and main secondary endpoints of all QUANTI studies.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now